Editas Medicine (EDIT) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Editas Medicine Announces Third Quarter 2016 Results and Update
November 7, 2016 4:01 PM ESTFurther strengthened leadership team with appointments of Charles Albright, Ph.D., as Chief Scientific Officer, and Gerald Cox, M.D., Ph.D., as Chief Medical Officer
CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30, 2016, and provided an update on recent accomplishments and upcoming events.
We made important progress in the third quarter of 2016 across all three of our key strategic objectives, said Katrine Bosley, President and Chief Executive Officer of Editas... More
